Metraipolis › archive › dc_b16fa105ea86

Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study — Europe PMC PMID:42625890

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42625890
DOI
10.3389/fmed.2026.1891244
License (as archived)
solo-consultazione
Archived
2026-10-17T01:20:37.550Z
SHA-256 of the archived text
f104a73156e3f7d9c3aeb897268165f6dcb8bebb3a0bbbfab0f87867344c0eff
Stable URL of this page
https://metraipolis.com/documento/dc_b16fa105ea86

How to cite

Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study — Europe PMC PMID:42625890 — Europe PMC (en), https://europepmc.org/article/MED/42625890 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b16fa105ea86 (Metraipolis archive dc_b16fa105ea86, sha256 f104a73156e3f7d9c3aeb897268165f6dcb8bebb3a0bbbfab0f87867344c0eff)
BibTeX
@misc{dcb16fa105ea86,
  title = {Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study — Europe PMC PMID:42625890},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42625890},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b16fa105ea86; sha256 f104a73156e3f7d9c3aeb897268165f6dcb8bebb3a0bbbfab0f87867344c0eff},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42625890. Agents can read the archived copy with the MCP tool read_document.